Clinical Trial Update: Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL [Phase 2]

View source ↗

Summary

Phase 2 study evaluating azacitidine with or without birinapant in patients with Myelodysplastic syndrome or Chronic myelomonocytic leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Birinapant

Snippet

Sponsor: TetraLogic Pharmaceuticals | Conditions: Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Status: TERMINATED